Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PanDox: ThermoDox and Focused Ultrasound for Pancreatic Cancer
NCT04852367Phase 1Withdrawn
- Sponsor
- University of Oxford
- Start
- Jun 2021
- Primary completion
- Mar 2023
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of doxorubicin in pancreatic adenocarcinoma (PDAC), sponsored by University of Oxford. Planned start Jun 2021; status: withdrawn.
02
Drugs
doxorubicin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04852367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04852367.